Immuneering

IMRX

Market cap $353M

Immuneering Corporation - Special Call Company Participants Benjamin Zeskind - Co-Founder, President, CEO & Director Conference Call Participants Laurence Watts Jay Olson - Oppenheimer & Co. Inc., Research Division Poorna Kannan - Needham & Company, LLC, Research Division Presentation Operator Hello, and welcome to the Immuneering conference call to discuss the positive 9-month update announced last week from the company's ongoing Phase IIa trial of atebemetinib and first-line pancreatic cancer patients. [Operator Instructions] As a reminder, this call is being recorded today, Monday, September 29, 2025.

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up.

Immuneering Corporation is upgraded to a Strong Buy due to positive phase 2a data for atebimetinib in 1st-line RAS-mutant pancreatic cancer. IMRX's atebimetinib plus mGnP achieved superior 9-month overall survival (86%) and progression-free survival (53%) compared to standard of care. Key catalysts include expected FDA feedback in Q4 2025, potential phase 3 initiation by end of 2025, and expansion into other solid tumors and NSCLC.

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Placement to Sanofi

- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced positive updated survival and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N=34), with 9 months median follow up.

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J.

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Septe

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement.

IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.